1. In Vivo
  2. >>COVID-19

How COVID-19 Disrupted The Clinical Trial Status Quo

 
• By Daniel Chancellor

As the world begins its transition into a post-pandemic existence, it becomes possible to look back on the past two years and begin to quantify the effects COVID-19 has brought. For the biopharmaceutical industry, clinical trials have been at the forefront.

clinical trial
• Source: Alamy

From waves of infection causing inaccessible sites and reduced patient availability, through to the unprecedented development of vaccines and other therapeutics, COVID-19 has permanently changed the nature of clinical research.

Clinical trials have historically been entirely concentrated around the clinical site, typically an academic or general hospital, employing experienced investigators...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

 
• By Eleanor Malone

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

COVID To GLP-1: Catalent Plants Ride With Novo To Next Public Health Crisis

 
• By Bowman Cox

A complex transformation is underway as client proposes to acquire CDMO facilities that vaccinated the world against the COVID-19 pandemic for pivot to the obesity epidemic.

Outlook 2024: Biopharma Embraces New Markets And New Tech

 
• By Lucie Ellis-Taitt

New markets, a patent cliff, an M&A rebound and clinical trial catalysts. How will it all play out for the biopharma sector in 2024? 

After All The Layoffs, Is Biopharma’s Headcount Still Growing?

 
• By Andrew McConaghie

While biotech layoffs and big pharma restructuring dominate the news in 2023, the sector’s job market remains buoyant.

More from In Vivo

CRL Trio Brings Shifting Sand To Regenerative Medicine Regulation

 
• By Bridget Silverman

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.

When VC Steps Back: Finding Alternative Biotech Funding

 
• By Jo Shorthouse

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal

 
• By Jo Shorthouse

MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. In this episode, its CEO and CFO discuss the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.